| Name | Title | Contact Details |
|---|
American Feeding Systems Inc is a Machinery company located in 15425 Endeavor Drive, Noblesville, Indiana, United States.
Bimeda is an Ireland-based company that develops, manufactures and markets veterinary and animal care products.
MPI began with a simple premise -- that ordering metal building supplies could be fast, easy and cost-effective. We knew that builders and contractors faced challenges every day, and we didnt need to be one of them. Since 2001, MPI has been driven to manufacture quality metal panels and building supplies, while continuously improving the customer experience along the way. Metal Panels Inc. is a leading manufacturer of quality metal panels for metal roofing, post-frame, metal building and commercial applications. 15 panels profiles available including curved panels, custom trim produced up to 21. In-plant manufacturing with portable roll-formers for on-site production available. Locations in Tulsa, OK and Kansas City, KS, serving northern Texas, Oklahoma, Kansas, Missouri, Arkansas, Southern Nebraska and Iowa. MPI supplies the metal contractor with everything they need from the slab up.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.